---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-060130"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:02:45.739443+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics Q1 net loss $41.9M on $29.6M IPR&D charge; cash $102M

## Summary
- Net loss $41.9M ($10.4M Q1'22); includes $29.6M IPR&D charge from Flame acquisition.
- R&D expense $38.9M, G&A $3.8M; cash $102.0M at Mar 31, 2023.
- Completed Part A enrollment in Phase 2 DeFianCe study of DKN-01 in CRC; initial data mid-2023.
- Acquired Flame Biosciences, adding anti-Claudin18.2 candidate FL-301 and ~$50M cash.
- Will present updated long-term data from DisTinGuish study in GEA at ASCO June 5, 2023.

## SEC filing metadata
- accession: 0001104659-23-060130
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465923060130/0001104659-23-060130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465923060130/tm2315622d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-060130
- JSON: https://secwatch.observer/filing/0001104659-23-060130.json
- Plain text: https://secwatch.observer/filing/0001104659-23-060130.txt

## Key facts
- Earnings Releases
  CYPHERPUNK TECHNOLOGIES INC. reported first quarter ended March 31, 2023 results: net income Net Loss was $41.9 million.
  - Period: first quarter ended March 31, 2023
  - Net income: Net Loss was $41.9 million
  - Result: reported results
  source text: On May 15, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465923060130/0001104659-23-060130-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.